Fundraising Fox
PhotoPharmics, Inc.
Salt Lake City, US · Founded 2011 · Delaware corporation · 2 known investors
Find your way into PhotoPharmics, Inc.
Sign up to find every way you can get introduced to PhotoPharmics, Inc.
- Your email: who you already know at PhotoPharmics, Inc., and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the PhotoPharmics, Inc. team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
PhotoPharmics is a clinical-stage medical device company developing non-invasive, light-based photo-neuromodulation therapies for neurodegenerative disease, with a focus on Parkinson's disease. Its investigational device Celeste delivers light through the eyes at home and is being evaluated in clinical trials targeting non-motor symptoms such as sleep, fatigue, and mood.
Founders & leadership
Board
Investors · 2
Funding
SEC filings, press & company announcements$42.4M disclosed across 6 of 7 rounds · 2015–2025
- Undisclosed amountSeries B extensionApr 2025Source ↗
▶$26.2MraisedNov 2025 · 47 investors · BiotechnologyRule 506(b)
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $26.3M
- Amount sold
- $26.2M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedDec 2020 · 9 investors · Other TechnologyRule 506(b)
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedOct 2019 · 24 investors · Other TechnologyRule 506(b)
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $6.6M
- Amount sold
- $6.6M
- First sale
- Sep 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.7MraisedMar 2017 · 18 investors · Other TechnologyRule 506(b)
- Kent SavageExecutive Officer, Director
- Ted StanleyDirector
- Gavin ChristensenDirector
- Daniel AdamsDirector
- Offering amount
- $2.8M
- Amount sold
- $2.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.3MraisedFeb 2017 · 15 investors · Other TechnologyRule 506(b)
- Ted StanleyDirector
- Gavin ChristensenDirector
- Kent SavageExecutive Officer, Director
- Daniel AdamsDirector
- Offering amount
- $2.3M
- Amount sold
- $2.3M
- First sale
- Jan 2017
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedJul 2015 · 15 investors · Other TechnologyRule 506(b)
- Ted StanleyDirector
- Daniel AdamsDirector
- Kent SavageExecutive Officer, Director
- Gavin ChristensenDirector
- Offering amount
- $2.7M
- Amount sold
- $2.1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2011
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $320K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does PhotoPharmics, Inc. do?
- PhotoPharmics is a clinical-stage medical device company developing non-invasive, light-based photo-neuromodulation therapies for neurodegenerative disease, with a focus on Parkinson's disease. Its investigational device Celeste delivers light through the eyes at home and is being evaluated in clinical trials targeting non-motor symptoms such as sleep, fatigue, and mood.
- Who are PhotoPharmics, Inc.'s investors?
- PhotoPharmics, Inc.'s investors include Kickstart, UpStart Ventures.
- How much funding has PhotoPharmics, Inc. raised?
- PhotoPharmics, Inc. has disclosed $42.4M raised across 6 of its 7 known rounds.
- Where is PhotoPharmics, Inc. headquartered?
- PhotoPharmics, Inc. is headquartered in Salt Lake City, US.